Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
J Exp Clin Cancer Res. 2018 Nov 19;37(1):278. doi: 10.1186/s13046-018-0933-x.
Melanoma, the most aggressive form of skin cancer, is characterized by high rates of metastasis, drug resistance and mortality. Here we investigated the role of Semaphorin 5A (Sema5A) on the properties associated with melanoma progression and the factors involved in Sema5A regulation.
Western blotting, qRT-PCR, Chromatin immunoprecipitation (ChIP) assay, immunohistochemistry of melanoma patient specimens and xenograft tissues, in vitro Transwell assay for cell migration and invasion evaluation, in vitro capillary-like structure formation analysis.
A significant correlation of Sema5A mRNA expression and melanoma progression was observed by analyzing GEO profile dataset. Endogenous Sema5A protein was detected in 95% of human melanoma cell lines tested, in 70% of metastatic specimens from patients affected by melanoma, and 16% of in situ melanoma specimens showed a focal positivity. We demonstrated that Sema5A regulates in vitro cell migration and invasion and the formation of vasculogenic structures. We also found an increase of Sema5A at both mRNA and protein level after forced expression of Bcl-2. By use of transcriptional and proteasome inhibitors, we showed that Bcl-2 increases the stability of Sema5A mRNA and protein. Moreover, by ChIP we demonstrated that Sema5A expression is under the control of the transcription factor c-Myb and that c-Myb recruitment on Sema5A promoter is increased after Bcl-2 overexpression. Finally, a concomitant decrease in the expression of Sema5A, Bcl-2 and c-Myb proteins was observed in melanoma cells after miR-204 overexpression.
Overall our data provide evidences supporting the role of Sema5A in melanoma progression and the involvement of Bcl-2, miR-204 and c-Myb in regulating its expression.
黑色素瘤是最具侵袭性的皮肤癌,其特点是转移率高、耐药性和死亡率高。在这里,我们研究了 Sema5A(Semaphorin 5A)在与黑色素瘤进展相关的特性以及调节 Sema5A 的因素中的作用。
通过分析 GEO 分析数据集,使用 Western blot、qRT-PCR、染色质免疫沉淀(ChIP)测定、黑色素瘤患者标本和异种移植物组织的免疫组织化学、体外 Transwell 测定细胞迁移和侵袭评估、体外毛细血管样结构形成分析检测 Sema5A 的表达。
通过分析 GEO 分析数据集,观察到 Sema5A mRNA 表达与黑色素瘤进展有显著相关性。在测试的 95%的人黑色素瘤细胞系中检测到内源性 Sema5A 蛋白,在 70%的转移性黑色素瘤患者标本中检测到,16%的原位黑色素瘤标本显示局灶性阳性。我们证明 Sema5A 调节体外细胞迁移和侵袭以及血管生成结构的形成。我们还发现,在强制表达 Bcl-2 后,Sema5A 的 mRNA 和蛋白水平均增加。通过使用转录和蛋白酶体抑制剂,我们表明 Bcl-2 增加了 Sema5A mRNA 和蛋白的稳定性。此外,通过 ChIP 我们证明 Sema5A 的表达受转录因子 c-Myb 的控制,并且在 Bcl-2 过表达后,c-Myb 募集到 Sema5A 启动子上增加。最后,在 miR-204 过表达后,黑色素瘤细胞中 Sema5A、Bcl-2 和 c-Myb 蛋白的表达同时降低。
总之,我们的数据提供了支持 Sema5A 在黑色素瘤进展中的作用的证据,并表明 Bcl-2、miR-204 和 c-Myb 参与调节其表达。